NRTX-1001
Phase 3Cell therapy
NRTX-1001 is one of 3 biologic programs targeting Temporal Lobe Epilepsy. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Temporal Lobe Epilepsy
#DrugCompanyPhaseTrials
1Lexapro
AbbVieApproved
Feraheme
AAzurity Pharmaceuticals
Approved
NRTX-1001
NNeurona Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NRTX-1001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 3[1]
- Company
- NNeurona Therapeutics